Last update 23 Jan 2025

Sanofi-Aventis Australia Pty Ltd.

Subsidiary Company|
1973|
Australia
|
www.sanofi.com.au

Overview

Tags

Other Diseases
Nervous System Diseases
Endocrinology and Metabolic Disease
Small molecule drug
Enzyme
Prophylactic vaccine

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases19
Endocrinology and Metabolic Disease19
Immune System Diseases14
Infectious Diseases12
Hemic and Lymphatic Diseases11
Neoplasms10
Top 5 Drug TypeCount
Small molecule drug16
Enzyme7
Monoclonal antibody5
Prophylactic vaccine5
Hormone4
Top 5 TargetCount
INSR(Insulin receptor)3
M6PR x α-glucosidase2
IDS(Iduronate-2-sulfatase)1
RSV F protein(Respiratory syncytial virus F protein)1
SMPD1(sphingomyelin phosphodiesterase 1)1

Related

43
Drugs associated with Sanofi-Aventis Australia Pty Ltd.
Nirsevimab
Target
RSV F protein
Mechanism
Respiratory syncytial virus F protein inhibitors
Active Org.
AstraZeneca PLCAstraZeneca PLC [+7]
Originator Org.
AstraZeneca AB
Active Indication
Respiratory Syncytial Virus Infections [+3]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
EU [+3]
First Approval Date31 Oct 2022
Olipudase alfa
Target
SMPD1
Mechanism
SMPD1 inhibitors
Active Org.
Genzyme Corp.Genzyme Corp. [+5]
Originator Org.
Genzyme Corp.Genzyme Corp.
Active Indication
Acid sphingomyelinase deficiency [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date28 Mar 2022
Avalglucosidase alfa
Target
M6PR x α-glucosidase
Mechanism
M6PR inhibitors [+1]
Active Org.
Genzyme Corp.Genzyme Corp. [+6]
Originator Org.
Genzyme Corp.Genzyme Corp.
Active Indication
Glycogen Storage Disease Type II
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date06 Aug 2021
3
Clinical Trials associated with Sanofi-Aventis Australia Pty Ltd.
ACTRN12624000274572
/ RecruitingNot Applicable
A multi-center, prospective, longitudinal cohort study of Chlamydia trachomatis infection and reinfection in adults aged 18 to 29 years.
ACTRN12623001176651
/ SuspendedPhase 1
A randomized, placebo-controlled, sequential, participant- and Investigator-masked Phase 1 study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics ( PD) of ascending single and multiple doses of SAR446422 in female and male healthy participants 18 to 55 years of age
ACTRN12622001387718
/ SuspendedPhase 1
A randomized, double-blind, placebo-controlled, phase 1, single centre, First-in-human, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single (SAD17442) and multiple (MAD17443) ascending, subcutaneous doses of SAR444559 in healthy adult participants.
100 Clinical Results associated with Sanofi-Aventis Australia Pty Ltd.
Login to view more data
0 Patents (Medical) associated with Sanofi-Aventis Australia Pty Ltd.
Login to view more data
100 Deals associated with Sanofi-Aventis Australia Pty Ltd.
Login to view more data
100 Translational Medicine associated with Sanofi-Aventis Australia Pty Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
1
42
Approved
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free